Gene mutation detection: guiding cancer selection of the right targeted treatment drug.

Lung cancer and colorectal cancer have become the leading causes of cancer death in most countries in recent years.
due to the differences in individual genetic genes, different types of cancer patients choose suitable targeted treatment drugs or can achieve the desired efficacy, gene mutation detection for doctors to provide important reference information.
China's State Food and Drug Administration has approved the cobas EGFR/KRAS gene mutation detection technology developed by Roche in Switzerland for clinical gene mutation status recognition, which has been approved by the United States, Germany, the United Kingdom, Singapore and other countries to market the testing technology.
lung cancer is most common in non-small cell lung cancer (NSCLC), including adenocarcinoma, scale cancer, etc.
EGFR is the main driving gene of Adenocarcinoma in East Asian descent, international clinical studies show that: tyrosine inhibitor class (TKI) targeted drugs for EGFR gene mutation of NSCLC patients more efficient than chemotherapy, EGFR gene mutation is a patient's sensitivity to targeted treatment of strong predictorfactor, eGFR testing before treatment helps guide clinical personalized drug use.
late-stage colorectal cancer anti-EGFR treatment can only play a role in KRAS wild patients, kraS testing before treatment can clearly distinguish the patient's genetic mutation status, guide individualized targeted treatment.
the European Society of Clinical Oncology, the American Society of Clinical Oncology, etc. have recommended EGFR gene mutation detection in patients with advanced NSCLC, and recommended THE use of KRAS gene mutation testing to select colorectal patients.
Source: Decoding Medicine.